{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T21:04:44Z","timestamp":1794258284673,"version":"4.9.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2020,4,23]],"date-time":"2020-04-23T00:00:00Z","timestamp":1587600000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,4,23]],"date-time":"2020-04-23T00:00:00Z","timestamp":1587600000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Dis"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Melanoma is a kind of tumor that originates from melanocytes and is characterized by chemoresistance and distant metastasis. Although the complete pathogenesis of melanoma remains unclear, increasing evidence suggests that circular RNAs (circRNAs) may be involved. In the present study, we identified a circular RNA, circ_0002770, which is produced from the well-known oncogene MDM2, and was sharply increased in melanoma and correlated with a poor prognosis. Knockdown of circ_0002770 suppressed melanoma cell invasion, migration and proliferation. Mechanistically, circ_0002770 acted as a sponge of miR-331-3p and could indirectly regulate DUSP5 and TGFBR1. Inhibition of miR-331-3p reversed the inhibitory effect of si-circ_0002770 on melanoma cell proliferation and invasion. In vivo evidence further confirmed that silencing circ_0002770 inhibited melanoma tumor formation. In conclusion, circ_0002770 facilitated melanoma cell proliferation, invasion and migration by sponging miR-331-3p and modulating DUSP5 and TGFBR1.<\/jats:p>","DOI":"10.1038\/s41419-020-2444-x","type":"journal-article","created":{"date-parts":[[2020,4,23]],"date-time":"2020-04-23T13:02:29Z","timestamp":1587646949000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["RETRACTED ARTICLE: Circ_0002770, acting as a competitive endogenous RNA, promotes proliferation and invasion by targeting miR-331-3p in melanoma"],"prefix":"10.1038","volume":"11","author":[{"given":"Peng","family":"Qian","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liu","family":"Linbo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhai","family":"Xiaomei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pei","family":"Hui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,4,23]]},"reference":[{"key":"2444_CR1","doi-asserted-by":"publisher","first-page":"330e","DOI":"10.1097\/PRS.0000000000002367","volume":"138","author":"SN Pavri","year":"2016","unstructured":"Pavri, S. N. et al. Malignant melanoma: beyond the basics. Plast. Reconstr. Surg.138, 330e\u2013340e (2016).","journal-title":"Plast. Reconstr. Surg."},{"key":"2444_CR2","first-page":"1005","volume":"28","author":"M Rastrelli","year":"2014","unstructured":"Rastrelli, M. et al. Melanoma: epidemiology, risk factors, pathogenesis, diagnosis and classification. Vivo28, 1005\u20131011 (2014).","journal-title":"Vivo"},{"key":"2444_CR3","doi-asserted-by":"publisher","first-page":"446e","DOI":"10.1097\/PRS.0b013e31829ad411","volume":"132","author":"WW Dzwierzynski","year":"2013","unstructured":"Dzwierzynski, W. W. Managing malignant melanoma. Plast. Reconstr. Surg.132, 446e\u2013460e (2013).","journal-title":"Plast. Reconstr. Surg."},{"key":"2444_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/978-3-319-22539-5_1","volume":"167","author":"B Shannan","year":"2016","unstructured":"Shannan, B. et al. Heterogeneity in melanoma. Cancer Treat. Res.167, 1\u201315 (2016).","journal-title":"Cancer Treat. Res."},{"key":"2444_CR5","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1684\/ejd.2016.2787","volume":"26","author":"S Ribero","year":"2016","unstructured":"Ribero, S., Glass, D. & Bataille, V. Genetic epidemiology of melanoma. Eur. J. Dermatol.26, 335\u2013339 (2016).","journal-title":"Eur. J. Dermatol."},{"key":"2444_CR6","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1089\/tmj.2017.0009","volume":"23","author":"M Wang","year":"2017","unstructured":"Wang, M. et al. Diagnosis and management of malignant melanoma in store-and-forward teledermatology. Telemed. J. E. Health23, 877\u2013880 (2017).","journal-title":"Telemed. J. E. Health"},{"key":"2444_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/j.1440-0960.2008.00496_1.x","volume":"50","author":"AA Marghoob","year":"2009","unstructured":"Marghoob, A. A. et al. The most common challenges in melanoma diagnosis and how to avoid them. Australas. J. Dermatol. 50, 1\u201313 (2009).","journal-title":"Australas. J. Dermatol"},{"key":"2444_CR8","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1177\/1535370217708978","volume":"242","author":"KY Hsiao","year":"2017","unstructured":"Hsiao, K. Y., Sun, H. S. & Tsai, S. J. Circular RNA - new member of noncoding RNA with novel functions. Exp. Biol. Med.242, 1136\u20131141 (2017).","journal-title":"Exp. Biol. Med."},{"key":"2444_CR9","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1007\/978-981-13-1426-1_4","volume":"1087","author":"N Eger","year":"2018","unstructured":"Eger, N. et al. Circular RNA splicing. Adv. Exp. Med. Biol.1087, 41\u201352 (2018).","journal-title":"Adv. Exp. Med. Biol."},{"key":"2444_CR10","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.canlet.2015.06.003","volume":"365","author":"S Qu","year":"2015","unstructured":"Qu, S. et al. Circular RNA: a new star of noncoding RNAs. Cancer Lett.365, 141\u2013148 (2015).","journal-title":"Cancer Lett."},{"key":"2444_CR11","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.pharmthera.2018.01.010","volume":"187","author":"B Han","year":"2018","unstructured":"Han, B., Chao, J. & Yao, H. Circular RNA and its mechanisms in disease: from the bench to the clinic. Pharm. Ther.187, 31\u201344 (2018).","journal-title":"Pharm. Ther."},{"key":"2444_CR12","first-page":"133","volume":"34","author":"Y Chen","year":"2017","unstructured":"Chen, Y. et al. [Circular RNA in human disease and their potential clinic significance]. Zhonghua Yi Xue Yi Chuan Xue Za Zhi34, 133\u2013137 (2017).","journal-title":"Zhonghua Yi Xue Yi Chuan Xue Za Zhi"},{"key":"2444_CR13","doi-asserted-by":"publisher","first-page":"2462","DOI":"10.1016\/j.bbrc.2017.12.146","volume":"495","author":"J Wu","year":"2018","unstructured":"Wu, J. et al. Hydrogen postconditioning promotes survival of rat retinal ganglion cells against ischemia\/reperfusion injury through the PI3K\/Akt pathway. Biochem. Biophys. Res. Commun.495, 2462\u20132468 (2018).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"2444_CR14","doi-asserted-by":"publisher","first-page":"656","DOI":"10.21147\/j.issn.1000-9604.2018.06.10","volume":"30","author":"X Yang","year":"2018","unstructured":"Yang, X. et al. Novel circular RNA expression profile of uveal melanoma revealed by microarray. Chin. J. Cancer Res.30, 656\u2013668 (2018).","journal-title":"Chin. J. Cancer Res."},{"key":"2444_CR15","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1002\/1878-0261.12468","volume":"13","author":"L Verduci","year":"2019","unstructured":"Verduci, L. et al. The circRNA-microRNA code: emerging implications for cancer diagnosis and treatment. Mol. Oncol.13, 669\u2013680 (2019).","journal-title":"Mol. Oncol."},{"key":"2444_CR16","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.bbrc.2018.05.114","volume":"502","author":"W Luan","year":"2018","unstructured":"Luan, W. et al. circRNA_0084043 promote malignant melanoma progression via miR-153-3p\/Snail axis. Biochem. Biophys. Res. Commun.502, 22\u201329 (2018).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"2444_CR17","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-11-85","volume":"11","author":"Z Chi","year":"2011","unstructured":"Chi, Z. et al. Clinical presentation, histology, and prognoses of malignant melanoma in ethnic Chinese: a study of 522 consecutive cases. BMC Cancer11, 85 (2011).","journal-title":"BMC Cancer"},{"key":"2444_CR18","doi-asserted-by":"publisher","first-page":"2283","DOI":"10.1007\/s00432-018-2726-1","volume":"144","author":"H Mishra","year":"2018","unstructured":"Mishra, H. et al. Melanoma treatment: from conventional to nanotechnology. J. Cancer Res. Clin. Oncol.144, 2283\u20132302 (2018).","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"2444_CR19","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1007\/978-3-319-22539-5_8","volume":"167","author":"MA Wilson","year":"2016","unstructured":"Wilson, M. A. & Schuchter, L. M. Chemotherapy for melanoma. Cancer Treat. Res.167, 209\u2013229 (2016).","journal-title":"Cancer Treat. Res."},{"key":"2444_CR20","doi-asserted-by":"publisher","unstructured":"Abi, A. et al. Circular RNAs: epigenetic regulators in cancerous and noncancerous skin diseases. Cancer Gene Ther.https:\/\/doi.org\/10.1038\/s41417-019-0130-x (2019).","DOI":"10.1038\/s41417-019-0130-x"},{"key":"2444_CR21","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1007\/s12307-019-00230-4","volume":"12","author":"MR Fumagalli","year":"2019","unstructured":"Fumagalli, M. R. et al. Cross-talk between circRNAs and mRNAs modulates MiRNA-mediated circuits and affects melanoma plasticity. Cancer Microenviron.12, 95\u2013104 (2019).","journal-title":"Cancer Microenviron."},{"key":"2444_CR22","doi-asserted-by":"publisher","first-page":"15608","DOI":"10.1073\/pnas.95.26.15608","volume":"95","author":"SN Jones","year":"1998","unstructured":"Jones, S. N. et al. Overexpression of Mdm2 in mice reveals a p53-independent role for Mdm2 in tumorigenesis. Proc. Natl. Acad. Sci. USA95, 15608\u201315612 (1998).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2444_CR23","doi-asserted-by":"publisher","first-page":"3453","DOI":"10.1093\/nar\/26.15.3453","volume":"26","author":"J Momand","year":"1998","unstructured":"Momand, J. et al. The MDM2 gene amplification database. Nucleic Acids Res.26, 3453\u20133459 (1998).","journal-title":"Nucleic Acids Res."},{"key":"2444_CR24","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1038\/387296a0","volume":"387","author":"Y Haupt","year":"1997","unstructured":"Haupt, Y. et al. Mdm2 promotes the rapid degradation of p53. Nature387, 296\u2013299 (1997).","journal-title":"Nature"},{"key":"2444_CR25","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/S0014-5793(97)01480-4","volume":"420","author":"R Honda","year":"1997","unstructured":"Honda, R., Tanaka, H. & Yasuda, H. Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53. FEBS Lett.420, 25\u201327 (1997).","journal-title":"FEBS Lett."},{"key":"2444_CR26","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1038\/bjc.2017.433","volume":"118","author":"CE Wu","year":"2018","unstructured":"Wu, C. E. et al. Targeting negative regulation of p53 by MDM2 and WIP1 as a therapeutic strategy in cutaneous melanoma. Br. J. Cancer118, 495\u2013508 (2018).","journal-title":"Br. J. Cancer"},{"key":"2444_CR27","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1016\/j.ccell.2016.09.019","volume":"30","author":"M Lu","year":"2016","unstructured":"Lu, M. et al. Restoring p53 function in human melanoma cells by inhibiting MDM2 and cyclin B1\/CDK1-phosphorylated nuclear iASPP. Cancer Cell30, 822\u2013823 (2016).","journal-title":"Cancer Cell"},{"key":"2444_CR28","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/j.biopha.2018.08.152","volume":"108","author":"D Bian","year":"2018","unstructured":"Bian, D., Wu, Y. & Song, G. Novel circular RNA, hsa_circ_0025039 promotes cell growth, invasion and glucose metabolism in malignant melanoma via the miR-198\/CDK4 axis. Biomed. Pharmacother.108, 165\u2013176 (2018).","journal-title":"Biomed. Pharmacother."},{"key":"2444_CR29","first-page":"10918","volume":"23","author":"Y Zou","year":"2019","unstructured":"Zou, Y. et al. CircRNA_0016418 expedites the progression of human skin melanoma via miR-625\/YY1 axis. Eur. Rev. Med. Pharm. Sci.23, 10918\u201310930 (2019).","journal-title":"Eur. Rev. Med. Pharm. Sci."},{"key":"2444_CR30","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.3892\/or.2015.4450","volume":"35","author":"D Zhao","year":"2016","unstructured":"Zhao, D., Sui, Y. & Zheng, X. MiR-331-3p inhibits proliferation and promotes apoptosis by targeting HER2 through the PI3K\/Akt and ERK1\/2 pathways in colorectal cancer. Oncol. Rep.35, 1075\u20131082 (2016).","journal-title":"Oncol. Rep."},{"key":"2444_CR31","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1093\/carcin\/bgy074","volume":"39","author":"X Chen","year":"2018","unstructured":"Chen, X. et al. miR-331-3p functions as an oncogene by targeting ST7L in pancreatic cancer. Carcinogenesis39, 1006\u20131015 (2018).","journal-title":"Carcinogenesis"}],"updated-by":[{"DOI":"10.1038\/s41419-024-06846-9","type":"retraction","label":"Retraction","source":"publisher","updated":{"date-parts":[[2024,6,24]],"date-time":"2024-06-24T00:00:00Z","timestamp":1719187200000}}],"container-title":["Cell Death &amp; Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41419-020-2444-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-020-2444-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-020-2444-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,25]],"date-time":"2024-06-25T08:02:20Z","timestamp":1719302540000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41419-020-2444-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,23]]},"references-count":31,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2020,4]]}},"alternative-id":["2444"],"URL":"https:\/\/doi.org\/10.1038\/s41419-020-2444-x","relation":{},"ISSN":["2041-4889"],"issn-type":[{"value":"2041-4889","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,4,23]]},"assertion":[{"value":"18 January 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 March 2020","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 March 2020","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 April 2020","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 June 2024","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This article has been retracted. Please see the Retraction Notice for more detail:","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1038\/s41419-024-06846-9","URL":"https:\/\/doi.org\/10.1038\/s41419-024-06846-9","order":8,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"264"}}